Nicotine Pouches Create Opportunity for Pharmacist Counseling

Marketed as a cleaner alternative to cigarettes and smokeless tobacco, new evidence suggests nicotine pouches carry their own set of risks that pharmacists are uniquely positioned to address. According to a recent JAPhA study of the growing nicotine market, these pouches have demonstrated minimal nicotine cessation effects while posing significant risks in youth initiation, dual nicotine use, and more.¹

“Oral nicotine pouches are one of the fastest-growing nicotine product categories, and some people are dual-using with e-cigarettes or cigarettes,” according to Truth Initiative.² “At the same time, illegal and disposable e-cigarettes continue to proliferate, offering more nicotine at cheaper prices. In the US, only 45 e-cigarettes and 26 oral nicotine products are authorized for sale by the FDA, making most products on the market illegal.”

The commercial explosion of oral nicotine pouches is driven by massive shifts in retail sales and aggressive marketing strategies. Retail data show that the amount of nicotine sold through oral pouches surged from under 4 kilograms in 2017 to over 3000 by early 2024, eclipsing even disposable e-cigarettes in total nicotine volume sold by weight.^2-4

Global sales for these products reached nearly $7 billion, with roughly 80% of that revenue generated in the US alone.⁴

READ MORE: How Language Shapes Harm Reduction

Although manufacturers frame these small sachets as discreet lifestyle accessories that leave no smell or teeth staining, public health researchers emphasize that pouches often contain high nicotine concentrations ranging up to 12 milligrams or more per pouch, far exceeding the dosage levels found in standard nicotine replacement therapy.^1,4

Rising Youth Uptake and the Biohacking Myth

Beyond adult smokers, the rapid growth of nicotine pouches presents significant public health challenges regarding youth initiation and social media trends. Marketing campaigns across digital platforms and video-sharing channels frequently portray pouches as trendy energy boosters, while online influencers promote nicotine biohacking for enhanced cognitive focus.^1,2,4,5

Health experts from the American Lung Association caution that nicotine is a potent cardiovascular stimulant rather than a benign cognitive tool, noting that its 2-hour half-life accelerates tolerance and dependency while narrowing blood vessels and posing severe developmental harms to individuals under 25.⁵

Furthermore, pediatric poison control records indicate a dramatic increase in accidental ingestions of high-strength pouches among children under 6 years old, resulting in heightened risks of serious medical outcomes and hospital admissions.¹

Evaluating Harm Reduction vs Cessation Reality

Although chemical analyses confirm that tobacco-free pouches expose users to fewer combustion-related toxicants than traditional cigarettes, systematic reviews reveal a stark gap between potential harm reduction and actual clinical outcomes. Clinical trials published in JAPhA indicate that no randomized controlled trial has demonstrated statistically significant smoking cessation efficacy for nicotine pouches compared with FDA-approved cessation aids or control groups.^1,3

Instead of achieving complete substitution, the vast majority of consumers engage in dual use by combining pouches with combustible cigarettes or electronic vaping devices, a behavioral pattern that maintains nicotine addiction without delivering meaningful health benefits.¹

Experts also observe that because pouches can be consumed discreetly in smoke-free environments, like the workplace or airplanes, users often maintain persistently elevated blood-nicotine levels throughout the day, ultimately deepening dependence rather than facilitating a path to quit.^4,5

The Role of Pharmacist Interventions

As frontline health care providers, community pharmacists possess an opportunity to clear up patient misconceptions and deliver evidence-based counseling. Guidance from the International Pharmaceutical Federation (FIP) underscores that pharmacists should proactively identify tobacco and nicotine usage, assess patient readiness to quit, and provide structured behavioral support alongside approved pharmacotherapy.^1,3

When encountering patients interested in oral pouches, pharmacists must clarify that FDA market authorization reflects reduced toxicant exposure relative to cigarettes, rather than an endorsement of cessation efficacy. Clinicians can screen for dual-use patterns, educate families on child-resistant storage practices, and steer patients toward proven first-line cessation tools.^1,3,5

By establishing tobacco-free environments and guiding patients away from unapproved recreational products, pharmacists remain central to building a future free from nicotine dependence, as noted by FIP.³

READ MORE: Mental and Behavioral Health Resource Center

REFERENCES

1. Souza EF, Parang K. Nicotine pouches: harm reduction or initiation pathway? a pharmacy-focused review. JAPhA. August 1, 2026:103517. doi:10.1016/j.japh.2026.103517

2. Huge rise in nicotine sold through oral nicotine pouches. Truth Initiative. April 30, 2026. Accessed September 16, 2026. https://truthinitiative.org/research-resources/emerging-tobacco-products/huge-rise-nicotine-sold-through-oral-nicotine-pouches

3. FIP statement of policy: the role of the pharmacist in establishing a future free from tobacco and nicotine dependence. International Pharmaceutical Federation. May 31, 2024. Accessed September 16, 2026. https://www.fip.org/file/6049

4. Sherwood CH. Stanford expert explains surge in nicotine pouches. Stanford Report. June 10, 2026. Accessed September 16, 2026. https://news.stanford.edu/stories/2026/06/nicotine-pouches-medical-expert-facts

5. The severe dangers of nicotine biohacking. American Lung Association. April 20, 2026. https://www.lung.org/blog/nicotine-biohack-dangers